If approved, CagriSema would become the first GLP-1 and amylin combination product to reach the market for obesity, a genuinely novel mechanism designation that Novo Nordisk regards as a meaningful point of differentiation regardless of the tirzepatide comparison
Dietary changes during GLP-1 therapy and implications for the microbiome Research suggests that microbial shifts may follow metabolic improvements linked to weight loss, indicating they are more likely secondary effects rather than primary drivers of GLP-1-induced weight reduction
CJC-1295 (no DAC) + Ipamorelin (10mg) is currently in stock at Aussie Peptides and available for domestic dispatch across Australia
The effect of selenium on thyroid status in a population with marginal selenium and iodine status
Anakinra, as a recombinant IL-1 receptor antagonist, can block the biological activity of IL-1 and IL-1, thereby inhibiting the inflammatory cascade (Szabo et al., 2022)
Surprisingly, this is not due to heme-induced activation of HRI, but rather triggered by DELE1, although there are some key differences with the established model
.png)
